Drugs / diepalrestat
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2/3 | NCT02332005 Comparator | Nov 2014 → Nov 2017 | diabetic polyneuropathy | NeuromaxBionevia | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | diepalrestat | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02332005 ↗ |
| Action | Inhibit | “aldose reductase inhibitor” NCT02332005 ↗ |
| Route | Oral | “twice daily an oral dose of diepalrestat” NCT02332005 ↗ |